ERZOFRI EXTENDED-RELEASE — LUYE INNOMIND PHARMA, approved 2025-01-22 (NDA216352).
19,805 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.